Lixte Biotechnology Files an IND with the FDA to Conduct a Phase 1b/2 Trial of LB-100 in Patients with Myelodysplastic Syndrome at Moffitt Cancer Center

EAST SETAUKET, NY , Oct. 09, 2018 -- (Healthcare Sales & Marketing Network) -- Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced that it has submitted an IND to the FDA to conduct a Phase 1b/2 trial of the safety and therapeutic benefit of Lixte’s... Biopharmaceuticals, Oncology, FDA Lixte Biotechnology, protein phosphatases, Myelodysplastic Syndrome

Source: HSMN NewsFeed - October 9, 2018 Category: Pharmaceuticals Source Type: news